Archives of Virology

, Volume 163, Issue 3, pp 609–616 | Cite as

Evaluation of the associations between endothelial dysfunction, inflammation and coagulation in Crimean-Congo hemorrhagic fever patients

  • Halef Okan Doğan
  • Seyit Ali Büyüktuna
  • Sercan Kapancik
  • Sevtap Bakir
Original Article


Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic viral disease. The aim of this study was to evaluate the association between inflammation, coagulation and endothelial dysfunction in CCHF. The study population consisted of 40 patients and 50 healthy controls. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), endocan, high sensitive C-reactive protein (hsCRP), international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (aPTT) and platelets values were determined in blood samples. Median hsCRP (p < 0.0001), ALT (p < 0.001), AST (p < 0.001) and aPTT (p < 0.001) values were found to be higher in CCHF patients than in the healthy control subjects. In contrast, median endocan (p = 0.0006) and platelet (p < 0.001) concentrations were found to be lower in CCHF patients than in healthy controls. Serum hsCRP concentrations positively correlated with PT, aPTT and INR in CCHF patients, whereas serum endocan levels were not correlated with hsCRP, PT, aPTT and INR. In conclusion, endothelial dysfunction is one of the key steps in CCHF disease development and serum endocan may be used as a biomarker to evaluate endothelial dysfunction in patients. There is no relationship between increased inflammation and endothelial dysfunction. Coagulation abnormalities might be related to the impaired hepatic synthetic function of coagulation factors. Increased hsCRP concentrations may have a compensatory role in restoring impaired hemostasis in CCHF. Further research is needed to confirm these findings and to examine possible explanations.


Compliance with ethical standards

Conflict of interest

The authors have no conflict of interests to declare.

Ethical approval

In this study, the protocol was approved by the institutional ethics committee of Cumhuriyet University, as mentioned in the paper. Written informed consent was obtained from all participants. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


No financial support was received for this study.


  1. 1.
    Akinci E, Bodur H, Sunbul M, Leblebicioglu H (2016) Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever. Antivir Res 132:233–243. CrossRefPubMedGoogle Scholar
  2. 2.
    Çevik MA, Erbay A, Bodur H et al (2008) Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 12:374–379. CrossRefPubMedGoogle Scholar
  3. 3.
    Whitehouse CA (2004) Crimean-Congo hemorrhagic fever. Antivir Res 64:145–160. CrossRefPubMedGoogle Scholar
  4. 4.
    Karti SS, Odabasi Z, Korten V et al (2004) Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 10:1379–1384CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ergönül Ö (2006) Crimean-Congo haemorrhagic fever. Lancet Infect Dis 6:203–214CrossRefPubMedGoogle Scholar
  6. 6.
    Bente DA, Forester NL, Watts DM et al (2013) Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir Res. PubMedGoogle Scholar
  7. 7.
    Wight TN, Kinsella MG, Qwarnström EE (1992) The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 4:793–801CrossRefPubMedGoogle Scholar
  8. 8.
    Filep JG (2006) Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? Crit Care Med 34:574–575CrossRefPubMedGoogle Scholar
  9. 9.
    Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:1–8. CrossRefGoogle Scholar
  10. 10.
    Scherpereel A, Depontieu F, Grigoriu B et al (2006) Endocan, a new endothelial marker in human sepsis. Crit Care Med 34:532–537CrossRefPubMedGoogle Scholar
  11. 11.
    Spillmann D (2001) Heparan sulfate: anchor for viral intruders? Biochimie 83(8):811–817CrossRefPubMedGoogle Scholar
  12. 12.
    Grigoriu BD, Depontieu F, Scherpereel A et al (2006) Endocan expression and relationship with survival in human non small cell lung cancer. Clin Cancer Res 12:4575–4583. CrossRefPubMedGoogle Scholar
  13. 13.
    Sarrazin S, Adam E, Lyon M et al (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37. PubMedGoogle Scholar
  14. 14.
    Lassalle P, Molet S, Janin A et al (1996) ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 271:20458–20464. CrossRefPubMedGoogle Scholar
  15. 15.
    Altintas N, Mutlu LC, Akkoyun DC et al (2016) Effect of CPAP on new endothelial dysfunction marker, endocan. People with obstructive sleep apnea. Angiology 67(4):364–374. CrossRefPubMedGoogle Scholar
  16. 16.
    Bechard D, Gentina T, Delehedde M, Scherpereel A et al (2001) Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 276:48341–48349. CrossRefPubMedGoogle Scholar
  17. 17.
    Ridker PM (2005) C-reactive protein, inflammation, and cardiovascular disease: clinical update. Curr Issues Cardiol 32:384–386Google Scholar
  18. 18.
    Deodhar S (1989) C-Reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med 56:126–130CrossRefPubMedGoogle Scholar
  19. 19.
    Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW (1999) C-Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972–978. CrossRefPubMedGoogle Scholar
  20. 20.
    Schalkwijk CG, Poland DCW, Van Dijk W et al (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357. CrossRefPubMedGoogle Scholar
  21. 21.
    Devaraj S, Xu D, Jialal I (2003) C-Reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107:398–404. CrossRefPubMedGoogle Scholar
  22. 22.
    Wu J, Stevenson MJ, Brown JM et al (2008) C-Reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol 28:698–704. CrossRefPubMedGoogle Scholar
  23. 23.
    Cirillo P, Golino P, Calabrò P et al (2005) C-Reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 68:47–55. CrossRefPubMedGoogle Scholar
  24. 24.
    Cermak J, Key NS, Bach RR et al (1993) C-Reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82:513–520. papers3://publication/uuid/1B1B9252-69D3-4DCE-BC48-75A6483C38A6Google Scholar
  25. 25.
    Gris J-C, Faillie J-L, Cochery-Nouvellon É et al (2011) ISTH overt disseminated intravascular coagulation score in patients with septic shock: automated immunoturbidimetric soluble fibrin assay vs d-dimer assay. J Thromb Haemost 9:1252–1255. CrossRefPubMedGoogle Scholar
  26. 26.
    Vishwanath A, Quaiser S, Khan R (2016) Role of high-sensitivity C-reactive protein measurements in HIV patients. Indian J Sex Transm Dis AIDS 37:123. CrossRefGoogle Scholar
  27. 27.
    Bakır M, Gözel MG, Köksal I et al (2014) Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis 34:325–330. CrossRefPubMedGoogle Scholar
  28. 28.
    Dokuzoguz B, Celikbas AK, Gök ŞE et al (2013) Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis 57:1270–1274. CrossRefPubMedGoogle Scholar
  29. 29.
    Kim JH, Park MY, Kim CN et al (2012) Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep 28:1701–1708. CrossRefPubMedGoogle Scholar
  30. 30.
    Maurage C-A, Adam E, Minéo J-F et al (2009) Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68:633–641. CrossRefPubMedGoogle Scholar
  31. 31.
    Carrillo LM, Arciniegas E, Rojas HR, Ramirez RE (2011) Immunolocalization of endocan during the endothelial–mesenchymal transition process. Eur J Histochem 55:73–77. CrossRefGoogle Scholar
  32. 32.
    Delehedde M, Devenyns L, Maurage CAVR (2013) Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol. PubMedPubMedCentralGoogle Scholar
  33. 33.
    Yilmaz G, Yilmaz H, Arslan M et al (2017) The prognostic significance of serum TGF-β1 levels in patients with Crimean-Congo hemorrhagic fever. J Med Virol 89:413–416. CrossRefPubMedGoogle Scholar
  34. 34.
    Arslan M, Yilmaz G, Mentese A et al (2017) Importance of endothelial dysfunction biomarkers in patients with Crimean-Congo hemorrhagic fever. J Med Virol. Google Scholar
  35. 35.
    Yilmaz G, Koksal I, Topbas M et al (2010) The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: Severity prediction criteria. J Clin Virol 47:361–365. CrossRefPubMedGoogle Scholar
  36. 36.
    Bakir M, Engin A, Kuskucu MA et al (2016) Relationship of plasma cell-free DNA level with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Med Virol 88:1152–1158. CrossRefPubMedGoogle Scholar
  37. 37.
    Roudnicky F, Poyet C, Wild P et al (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73:1097–1106. CrossRefPubMedGoogle Scholar
  38. 38.
    Rennel E, Mellberg S, Dimberg A et al (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294. CrossRefPubMedGoogle Scholar
  39. 39.
    Bodur H, Akıncı E, Öngürü P et al (2010) Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever. Int J Infect Dis 14:e704–e707. CrossRefPubMedGoogle Scholar
  40. 40.
    Chen C-C, Lee I-K, Liu J-W et al (2015) Utility of C-reactive protein levels for early prediction of dengue severity in adults. Biomed Res Int 2015:1–6. Google Scholar
  41. 41.
    McElroy AK, Erickson BR, Flietstra TD et al (2014) Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 210:558–566. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Sari I, Bakir S, Engin A et al (2013) Some acute phase reactants and cholesterol levels in serum of patient with Crimean-Congo haemorrhagic fever. Bosn J Basic Med Sci 13:21–26CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Seo K, Kitazawa T, Yoshino Y et al (2015) Characteristics of serum endocan levels in infection. PLoS One 10:e0123358. CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417–430. CrossRefPubMedGoogle Scholar
  45. 45.
    Mostafavi E, Pourhossein B, Chinikar S (2014) Clinical symptoms and laboratory findings supporting early diagnosis of Crimean-Congo hemorrhagic fever in Iran. J Med Virol 86:1188–1192. CrossRefPubMedGoogle Scholar
  46. 46.
    Parlak E, Ertürk A, Çağ Y et al (2015) The effect of inflammatory cytokines and the level of vitamin D on prognosis in Crimean-Congo hemorrhagic fever. Int J Clin Exp Med 8:18302–18310PubMedPubMedCentralGoogle Scholar
  47. 47.
    Demirpençe Ö, Doğan HO, Erşan S et al (2016) Presepsin levels of patients with Crimean-Congo hemorrhagic fever. Jpn J Infect Dis 69:505–509. CrossRefPubMedGoogle Scholar
  48. 48.
    Onguru P, Dagdas S, Bodur H et al (2010) Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality. J Clin Lab Anal 24:163–166. CrossRefPubMedGoogle Scholar
  49. 49.
    Chee YL, Crawford JC, Watson HG, Greaves M (2008) Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol 140:496–504. CrossRefPubMedGoogle Scholar
  50. 50.
    Singh U (2005) C-Reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25:2216–2221. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of MedicineCumhuriyet UniversitySivasTurkey
  2. 2.Department of Infectious Disease and Clinical Microbiology, Faculty of MedicineCumhuriyet UniversitySivasTurkey

Personalised recommendations